All Stories

  1. The future treatment landscape for advanced estrogen driven breast cancer

    Article • Asia-Pacific Journal of Clinical Oncology, March 2016, Wiley

    Dr Andrew D Redfern

  2. Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape

    Article • Asia-Pacific Journal of Clinical Oncology, March 2016, Wiley

    Dr Andrew D Redfern

  3. Inflammatory breast cancer: A decade of experience

    Article • Asia-Pacific Journal of Clinical Oncology, February 2016, Wiley

    Dr Andrew D Redfern

  4. Cancer services in Western Australia: A comparison of regional outcomes with metropolitan Perth

    Article • Australian Journal of Rural Health, August 2015, Wiley

    Dr Andrew D Redfern

  5. Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines

    Article • Cell Communication and Signaling, May 2015, Springer Science + Business Media

    Dr Andrew D Redfern

  6. Abstract P6-08-14: Bone mineral density change on aromatase inhibitors as a predictor of breast cancer recurrence

    Article • Cancer Research, April 2015, American Association for Cancer Research (AACR)

    Dr Andrew D Redfern

  7. Abstract OT3-1-03: An open-label, multicentre, phase IIIb study with intravenous administration of pertuzumab, subcutaneous trastuzumab, and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)

    Article • Cancer Research, April 2015, American Association for Cancer Research (AACR)

    Dr Andrew D Redfern

  8. Clinical Implications of Circulating Tumor Cells of Breast Cancer Patients: Role of Epithelial–Mesenchymal Plasticity

    Article • Frontiers in Oncology, February 2015, Frontiers

    Dr Andrew D Redfern

  9. An Inactivated Ross River Virus Vaccine Is Well Tolerated and Immunogenic in an Adult Population in a Randomized Phase 3 Trial

    Article • Clinical and Vaccine Immunology, December 2014, ASM Journals

    Dr Andrew D Redfern

  10. Evaluation of a Novel Nicotine Inhaler Device: Part 1--Arterial and Venous Pharmacokinetics

    Article • Nicotine & Tobacco Research, November 2014, Oxford University Press (OUP)

    Dr Andrew D Redfern

  11. Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

    Article • Asia-Pacific Journal of Clinical Oncology, October 2014, Wiley

    Dr Andrew D Redfern

  12. Capecitabine for ER-positive versus ER-negative breast cancer

    Article • Cochrane Database of Systematic Reviews, August 2014, Wiley

    Dr Andrew D Redfern

  13. Evaluation of a Novel Nicotine Inhaler Device: Part 2--Effect on Craving and Smoking Urges

    Article • Nicotine & Tobacco Research, July 2014, Oxford University Press (OUP)

    Dr Andrew D Redfern

  14. RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators

    Article • Proceedings of the National Academy of Sciences, April 2013, Proceedings of the National Academy of Sciences

    Dr Andrew D Redfern

  15. Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer

    Article • Asia-Pacific Journal of Clinical Oncology, January 2012, Wiley

    Dr Andrew D Redfern

  16. SLIRP, a Small SRA Binding Protein, Is a Nuclear Receptor Corepressor

    Article • Molecular Cell, June 2006, Elsevier

    Dr Andrew D Redfern